Continuing Education

Serial 99mTechnetium Pyrophosphate Scintigraphy and Multimodality Assessments After Different Doses of Tafamidis for Variant Transthyretin Cardiac Amyloidosis

December 22, 2022 Editor

Circulation: Heart Failure, Ahead of Print.

← Addressing the Unique Social and Structural Drivers of Hypertension Among Sexual Minority Adults in the United States
Reflections on the healthcare environment in 2022, and thoughts on the year ahead →